PUBLIC COMPANY
save$STOKStoke Therapeutics, Inc.
$STOK31.31-5.03%Bedford, MA, USupdated 12h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
- phase2An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
- phase2An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 1, 26SELLTicho Barry· CHIEF MEDICAL OFFICER−$60K↗
- Mar 20, 26SELLAllan Jonathan· GENERAL COUNSEL & CORP SEC−$292K↗
- Mar 20, 26SELLAllan Jonathan· GENERAL COUNSEL & CORP SEC−$21K↗
- Mar 19, 26SELLTicho Barry· CHIEF MEDICAL OFFICER−$44K↗
- Mar 18, 26SELLTicho Barry· CHIEF MEDICAL OFFICER−$191K↗
- Mar 18, 26SELLAllan Jonathan· GENERAL COUNSEL & CORP SEC−$132K↗
- Mar 18, 26SELLLeggett Thomas· Chief Financial Officer−$68K↗
- Mar 18, 26SELLHoitt Jason· Chief Patient Officer−$55K↗
- Mar 18, 26SELLTicho Barry· CHIEF MEDICAL OFFICER−$15K↗
- Mar 18, 26SELLAllan Jonathan· GENERAL COUNSEL & CORP SEC−$11K↗
- Mar 18, 26SELLLeggett Thomas· Chief Financial Officer−$5K↗
- Mar 18, 26SELLHoitt Jason· Chief Patient Officer−$4K↗
- Mar 18, 26SELLTicho Barry· CHIEF MEDICAL OFFICER−$3K↗
- Mar 18, 26SELLAllan Jonathan· GENERAL COUNSEL & CORP SEC−$2K↗
- Mar 18, 26SELLLeggett Thomas· Chief Financial Officer−$1K↗
- Mar 18, 26SELLHoitt Jason· Chief Patient Officer−$986↗
- Mar 17, 26SELLTicho Barry· CHIEF MEDICAL OFFICER−$117K↗
- Mar 17, 26SELLTicho Barry· CHIEF MEDICAL OFFICER−$86K↗
- Mar 17, 26SELLAllan Jonathan· GENERAL COUNSEL & CORP SEC−$81K↗
- Mar 17, 26SELLAllan Jonathan· GENERAL COUNSEL & CORP SEC−$60K↗
🐶 Hiring Signal
next earnings Nov 3, 2026
Where Stoke Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
News
no news has mentioned this company yet
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that